Insider Transactions in Q2 2023 at Oncternal Therapeutics, Inc. (ONCT)
Insider Transaction List (Q2 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 14
2023
|
Gunnar F. Kaufmann Chief Scientific Officer |
BUY
Open market or private purchase
|
Direct |
3,000
+3.07%
|
$0
$0.36 P/Share
|
|
Jun 12
2023
|
Gunnar F. Kaufmann Chief Scientific Officer |
BUY
Open market or private purchase
|
Direct |
25,000
+21.42%
|
$0
$0.35 P/Share
|
|
Apr 14
2023
|
James B Breitmeyer Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
50,000
+10.43%
|
$0
$0.3 P/Share
|
|
Apr 14
2023
|
Salim Yazji Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+2.95%
|
$0
$0.3 P/Share
|
|
Apr 13
2023
|
James B Breitmeyer Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
100,000
+40.56%
|
$0
$0.29 P/Share
|
|
Apr 13
2023
|
Salim Yazji Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+5.89%
|
$0
$0.28 P/Share
|
|
Apr 13
2023
|
Richard G Vincent Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
30,000
+16.05%
|
$0
$0.3 P/Share
|
|
Apr 13
2023
|
Chase C. Leavitt General Counsel/Secretary |
BUY
Open market or private purchase
|
Direct |
10,000
+8.55%
|
$0
$0.29 P/Share
|
|
Apr 12
2023
|
Salim Yazji Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+6.26%
|
$0
$0.28 P/Share
|
|
Apr 12
2023
|
Chase C. Leavitt General Counsel/Secretary |
BUY
Open market or private purchase
|
Direct |
15,000
+13.4%
|
$0
$0.29 P/Share
|